EP0706372A1 - In situ gel for therapeutic use - Google Patents

In situ gel for therapeutic use

Info

Publication number
EP0706372A1
EP0706372A1 EP94917868A EP94917868A EP0706372A1 EP 0706372 A1 EP0706372 A1 EP 0706372A1 EP 94917868 A EP94917868 A EP 94917868A EP 94917868 A EP94917868 A EP 94917868A EP 0706372 A1 EP0706372 A1 EP 0706372A1
Authority
EP
European Patent Office
Prior art keywords
composition according
composition
solution
drug
mos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94917868A
Other languages
German (de)
French (fr)
Inventor
Johan Carlfors
Katarina Edsman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB, Pharmacia AB filed Critical Pharmacia and Upjohn AB
Publication of EP0706372A1 publication Critical patent/EP0706372A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention is related to the field of slow release drug delivery systems for therapeutic use, especially in the ophthalmic field, and provides an aqueous liquid composition which in contact with a physiological solution forms a gel matrix which has been found to stay for a considerable time in the administration area, for instance the eye, without causing any problems to the patient.
  • This gel can be utilized for controlled continuous administration of drug over a prolonged period of time.
  • a composition according to the invention can be used in a number of situations, e.g. oral, buccal, nasal and vaginal administration, when a slow release system is advantageous but will in the following be discussed mainly in connection with it's ophthalmological use since the requirements here are especially high.
  • a solid implant containing the active drug is manufactured and delivered to the doctor or nurse for application onto the patient's conjunctiva, preferably under one of the eye lids.
  • These type of implants often have an outer membrane layer through which the drug is allowed to diffuse. The release rate depends on the membrane structure as well as the internal matrix in which the drug is incorporated.
  • compositions which at room temperature and below this value is liquid (non-solid) is instilled into the eye and due to the rise in temperature forms a polymer matrix, for instance a gel.
  • a polymer matrix for instance a gel.
  • Some systems have been disclosed which are physiologically acceptable and which form a gel in contact with a physiological salt solution, for instance a tear solution. It is readily appreciated that according to this concept potentially very useful systems for drug delivery are provided.
  • compositions of the type mentioned above in contrast to the teaching of the prior art are made hypotonic. Gels formed under these conditions have been found to stay considerably longer in the eye compared to gels formed at higher tonicity values, e.g. under isotonic conditions, hence providing a more efficient delivery system.
  • the invention is accordingly related to a liquid hypotonic ophthalmic solution comprising a pharmaceutically active drug and at least one hydrophilic polymer of the type which undergoes liquid-gel phase transition gelling in situ in contact with the physiological solution, for instance tear solution or humour solution when used for intraocular administration.
  • a method for administration of a drug is provided using a composition as defined in this specification.
  • the hydrophilic polymer is functionally defined by the ability of an aqueous solution of the polymer to form a solid polymer structure, for instance a gel, when the ionic strength is raised to physiological values.
  • components belonging to this group include polysaccharides and natural as well as synthetic polysaccharide derivatives.
  • the preferred component at present is an extracellular anionic heteropolysaccharide produced by the bacterium Pseudo onas elodea, known as gellan gum and marketed as GelriteTM.
  • the gel forming component may in more general terms be any component which before administration is a liquid but forms a gel upon contact with a physiological fluid due to exchange of components between said liquid and the physiological fluid.
  • Such exchange of components include but is not limited to proteins, such as lysozymes, and ionic components as discussed above.
  • concentration of the gel forming component in cases when Gelrite is used is preferably in the range of from 0.1 to 10 % by weight, especially 0.1-2 % by weight.
  • the non- solid composition containing the hydrophilic polymer solution is hypotonic. It has been found, however, that the tonicity should not be too low since this causes undesirable side- effects, such as more or less severe initial irritation when the composition is applied.
  • the osmolality of the non-solid composition should accordingly be lower than that of an isotonic solution (about 290 mOs/kg) and a selected range according to this invention is from about 25 - 200 mOs/kg, preferably 25-150 mOs/kg and especially 50-150 mOs/kg.
  • the at present most prefered composition has a value around 100 mOs/kg.
  • the drug component contained in the composition should preferably be present as a dispersive system, either as a suspension of particles or as an emulsion.
  • the drug could be incorporated in or associated with carrier substances in the form of particles e.g. polymers (biodegradable, non- biodegradable or polymers which dissolve or degrade upon contact with a physiological fluid) , lipids or ion-exchange resins.
  • EP424042 is disclosed a system based on compositions of the Gelrite type in which the drug is present in particles which dissolve due to change in pH when the composition is instilled into the eye.
  • the pH and the buffering capacity of the composition being such that the neutralizing action of lachrymal fluid is sufficient for dissolving the solid microparticles.
  • the drug component contained in the composition could also be present as a solution. It may be solubilized by surfactants, lipids or by complex-forming agents.
  • the active drug to be administered according to the present invention can be chosen among a great number of components, for instance for ophthalmological use.
  • examples of such components include
  • - antihistaminics and decongestants for instance pyrilamine, tetrahydrazoline, antazoline and analogues thereof,
  • - anti-inflammatories such as flubiprofen, diclofenac, acetylsalicylic acid, cortisone, hydrocortisone, dexamethasone, prednisone, indomethacin and analogues thereof
  • antibacterial substances such as tetracyclines, penicillin, bacitracin, sulphonamides and analogues thereof,
  • cytotoxics for instance 5-fluorouracil
  • - antiglaucoma drugs for instance prostaglandins like the omega chain modified derivatives disclosed in EP0364417 (esp. 13, 14-dihydro-17-phenyl-18, 19,20-trinor-PGF2 ⁇ -isopropylester) and timolol, pilocarpine, epinephrine, dipivalylepinephrine, and their analogues.
  • prostaglandins like the omega chain modified derivatives disclosed in EP0364417 (esp. 13, 14-dihydro-17-phenyl-18, 19,20-trinor-PGF2 ⁇ -isopropylester) and timolol, pilocarpine, epinephrine, dipivalylepinephrine, and their analogues.
  • composition may contain other additives such as polymers, preservatives, nonionic tonicity agents, solubilizers, buffer agents, complexing agents and chelating agents.
  • additives such as polymers, preservatives, nonionic tonicity agents, solubilizers, buffer agents, complexing agents and chelating agents.
  • the composition also contained a small amount of fluorescent particles. The time these particles were detectable in the instillation area was measured and taken as an indication of the effectiveness of the drug delivery system.
  • a glycerol concentration of 3% is close to an isotonic solution and represents a comparison with a prior art system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical drug delivery composition, especially for ophthalmological use, comprising: a liquid hypotonic solution of at least one hydrophilic polymer of the type which undergoes liquid-gel phase transition gelling in situ in contact with a physiological solution, and a pharmaceutically active compound, as well as the use thereof for local administration of drugs.

Description

In situ gel for therapeutic use.
The present invention is related to the field of slow release drug delivery systems for therapeutic use, especially in the ophthalmic field, and provides an aqueous liquid composition which in contact with a physiological solution forms a gel matrix which has been found to stay for a considerable time in the administration area, for instance the eye, without causing any problems to the patient. This gel can be utilized for controlled continuous administration of drug over a prolonged period of time.
A composition according to the invention can be used in a number of situations, e.g. oral, buccal, nasal and vaginal administration, when a slow release system is advantageous but will in the following be discussed mainly in connection with it's ophthalmological use since the requirements here are especially high.
There are a number of situations when topical administration of a drug to the eye would be the most efficient form of therapy and various drop solutions have been developed for this purpose. However, natural mechanisms such as tear rates and blinking, which are important for the protection of the eye by removing dust and contaminants from the surface of the eye, make drug delivery difficult.
A fairly large group of patients have considerable problems to instill a solution onto the eye by themself and the need for slow release systems has therefore been recognized for a long time. There are also a number of therapeutic situations where the efficacy of the drug would benefit from a prolonged occular contact time. According to one concept a solid implant containing the active drug is manufactured and delivered to the doctor or nurse for application onto the patient's conjunctiva, preferably under one of the eye lids. These type of implants often have an outer membrane layer through which the drug is allowed to diffuse. The release rate depends on the membrane structure as well as the internal matrix in which the drug is incorporated. According to another concept a composition which at room temperature and below this value is liquid (non-solid) is instilled into the eye and due to the rise in temperature forms a polymer matrix, for instance a gel. A somewhat similar approach utilizes the fact that certain polymer solutions in contact with salt ions form a gel. Some systems have been disclosed which are physiologically acceptable and which form a gel in contact with a physiological salt solution, for instance a tear solution. It is readily appreciated that according to this concept potentially very useful systems for drug delivery are provided. Laboratoires Merck, Sharp & Dohme-Chibret have in a series of patent applications described the use of components which undergo liquid-gel phase transition under the effect of an increase in the ionic strength, see for instance AU8663189, EP227494, EP424042 and EP437368. In EP227494 it is mentioned that the test substance fluorescein is still persisting 5 hours after instillation when administered in such a composition.
In these publications an extracellular anionic heteropolysaccharide produced by the bacterium Pseudomonas elodea, known by the name of gellan gum and marketed under the brand name Gelrite™, is presented as the most preferred gel formation component. An aqueous solution of the gel-forming components is prepared containing no or only a very small amount of ionic substances together with the drug in a suitable form and optionally a preservative. It is also pointed out that the non-solid composition should preferably be isotonic and a tonicity adjusting substance, for instance annitol, is added.
We have now surprisingly found that considerably improved drug delivery systems are obtained if compositions of the type mentioned above in contrast to the teaching of the prior art are made hypotonic. Gels formed under these conditions have been found to stay considerably longer in the eye compared to gels formed at higher tonicity values, e.g. under isotonic conditions, hence providing a more efficient delivery system.
The invention is accordingly related to a liquid hypotonic ophthalmic solution comprising a pharmaceutically active drug and at least one hydrophilic polymer of the type which undergoes liquid-gel phase transition gelling in situ in contact with the physiological solution, for instance tear solution or humour solution when used for intraocular administration.
In another aspect of the invention a method for administration of a drug is provided using a composition as defined in this specification.
The hydrophilic polymer is functionally defined by the ability of an aqueous solution of the polymer to form a solid polymer structure, for instance a gel, when the ionic strength is raised to physiological values. Examples of components belonging to this group include polysaccharides and natural as well as synthetic polysaccharide derivatives. The preferred component at present is an extracellular anionic heteropolysaccharide produced by the bacterium Pseudo onas elodea, known as gellan gum and marketed as Gelrite™. The gel forming component may in more general terms be any component which before administration is a liquid but forms a gel upon contact with a physiological fluid due to exchange of components between said liquid and the physiological fluid. Such exchange of components include but is not limited to proteins, such as lysozymes, and ionic components as discussed above. The concentration of the gel forming component in cases when Gelrite is used is preferably in the range of from 0.1 to 10 % by weight, especially 0.1-2 % by weight.
The inventive concept is as mentioned above that the non- solid composition containing the hydrophilic polymer solution is hypotonic. It has been found, however, that the tonicity should not be too low since this causes undesirable side- effects, such as more or less severe initial irritation when the composition is applied.
The osmolality of the non-solid composition should accordingly be lower than that of an isotonic solution (about 290 mOs/kg) and a selected range according to this invention is from about 25 - 200 mOs/kg, preferably 25-150 mOs/kg and especially 50-150 mOs/kg. The at present most prefered composition has a value around 100 mOs/kg.
The drug component contained in the composition should preferably be present as a dispersive system, either as a suspension of particles or as an emulsion. The drug could be incorporated in or associated with carrier substances in the form of particles e.g. polymers (biodegradable, non- biodegradable or polymers which dissolve or degrade upon contact with a physiological fluid) , lipids or ion-exchange resins.
In EP424042 is disclosed a system based on compositions of the Gelrite type in which the drug is present in particles which dissolve due to change in pH when the composition is instilled into the eye. The pH and the buffering capacity of the composition being such that the neutralizing action of lachrymal fluid is sufficient for dissolving the solid microparticles.
Examples of methods for producing lipid particles containing an ophthalmologically active substance are given in EP 437368.
The drug component contained in the composition could also be present as a solution. It may be solubilized by surfactants, lipids or by complex-forming agents.
The active drug to be administered according to the present invention can be chosen among a great number of components, for instance for ophthalmological use. Examples of such components include
- antihistaminics and decongestants, for instance pyrilamine, tetrahydrazoline, antazoline and analogues thereof,
- anti-inflammatories such as flubiprofen, diclofenac, acetylsalicylic acid, cortisone, hydrocortisone, dexamethasone, prednisone, indomethacin and analogues thereof
- antiparasitc and/or antiprotozoal compounds
- antibacterial substances such as tetracyclines, penicillin, bacitracin, sulphonamides and analogues thereof,
- mydriatics, for instance cyclopentanol and tropicamide
- cytotoxics, for instance 5-fluorouracil
- antiglaucoma drugs, for instance prostaglandins like the omega chain modified derivatives disclosed in EP0364417 (esp. 13, 14-dihydro-17-phenyl-18, 19,20-trinor-PGF2α-isopropylester) and timolol, pilocarpine, epinephrine, dipivalylepinephrine, and their analogues. - antivirals
- antioxidants
- anticataracts
- antiallergics
- anaesthetics
The composition may contain other additives such as polymers, preservatives, nonionic tonicity agents, solubilizers, buffer agents, complexing agents and chelating agents.
Examples.
The relevance of the concept was verified in a series of experiments in which compositions comprising
Gelrite (various concentrations)
Benzalkonium chloride 0.01 g and Glycerol (0 - 3%), for adjusting the tonicity, in 100 ml of ultrapure water
were instilled into one of the eyes of a healthy volounteer. For measuring the duration time, or contact time, the composition also contained a small amount of fluorescent particles. The time these particles were detectable in the instillation area was measured and taken as an indication of the effectiveness of the drug delivery system.
A glycerol concentration of 3% is close to an isotonic solution and represents a comparison with a prior art system.
It should be noticed that with no addition of the tonicity adjusting component, glycerol, initial pain for half a minute or even more was reported by the test persons. A composition for use in the eye should for this reason have an osmolatity value of at least 25 mOs/kg.
From the results presented above it can be concluded that considerably longer contact times have now been achieved compared to the results indicated in the prior art literature.

Claims

Claims
1. Pharmaceutical drug delivery composition comprising
- a liquid hypotonic solution of at least one hydrophilic polymer of the type which undergoes liquid-gel phase transition gelling in situ in contact with a physiological solution, and
- at least one pharmaceutically active compound.
2. Composition according to claim 1, wherein the concentration of polymer is 0.1-10 wt-%.
3. Composition according to claim 1 or 2, wherein the hydrophilic polymer is a polysaccharide, for instance gellan gum.
4. Composition according to any one of claims 1 to 3, wherein the osmolality is 25-200 mOs/kg.
5. Composition according to claim 4, wherein the osmolality is 25-150 mOs/kg.
6. Composition according to claim 5, wherein the osmolality is 50-150 mOs/kg.
7. Composition according to any one of claims 1-6, wherein the active drug is present as a solution or in the form of particles.
8. Composition according to claim 7, wherein the drug is incorporated in or associated with a polymeric matrix, complex- forming matrix, lipid matrix or ion-exchange resin.
9. Composition according to any one of claims 1-8 wherein the composition additionally contains one or more component selected from preservatives, solubilizing agents, non-ionic tonicity adjusting agents, pH-adjusting agents or complexing agents.
10. Composition according to any one of claims 1-9 which is intended for ophthalmological use and the physiological solution is lacrimal fluid or aqueous humour.
11. Method for local administration of a pharmacologically active drug characterized by the use of a composition according to any one of claims 1-10.
EP94917868A 1993-06-02 1994-06-01 In situ gel for therapeutic use Withdrawn EP0706372A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9301877A SE9301877D0 (en) 1993-06-02 1993-06-02 IN SITU GEL FOR THERAPEUTIC USE
SE9301877 1993-06-02
PCT/SE1994/000522 WO1994027578A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use

Publications (1)

Publication Number Publication Date
EP0706372A1 true EP0706372A1 (en) 1996-04-17

Family

ID=20390132

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94917868A Withdrawn EP0706372A1 (en) 1993-06-02 1994-06-01 In situ gel for therapeutic use

Country Status (6)

Country Link
EP (1) EP0706372A1 (en)
JP (1) JPH08510731A (en)
AU (1) AU6940594A (en)
CA (1) CA2164113A1 (en)
SE (1) SE9301877D0 (en)
WO (1) WO1994027578A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2248881A1 (en) * 1996-03-13 1997-09-18 Annouk Rozier Ophthalmological composition of the type which undergoes liquid-gel phase transition
FR2746014B1 (en) * 1996-03-13 1999-01-08 LIQUID-GEL PHASE TRANSITION TYPE OPHTHALMOLOGICAL COMPOSITION
FR2754712B1 (en) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab OPHTHALMIC COMPOSITIONS
WO1998023292A1 (en) * 1996-11-29 1998-06-04 Monsanto Company Lubricious self-standing (intact) gel for oral delivery of biologically-active ingredients
JP2004189731A (en) * 2002-11-26 2004-07-08 Taisho Pharmaceut Co Ltd Nasal drop
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
JP5304108B2 (en) * 2007-08-30 2013-10-02 大正製薬株式会社 Eye drops
DE102010023949A1 (en) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ lecithin microemulsion gel formulation
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US10398742B2 (en) 2014-12-15 2019-09-03 The Johns Hopkins University CVS transplantation for treatment of bacterial vaginosis
JP6846351B2 (en) * 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー Hypotonic hydrogel formulation for enhanced transport of active agents on mucosal surfaces
CN109260146A (en) * 2018-10-12 2019-01-25 广州大光制药有限公司 Ophthalmic solution sodium in situ forming eye type gel eyedrop and preparation method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (en) * 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
FR2657018A1 (en) * 1990-01-12 1991-07-19 Merck Sharp & Dohme FLUID OPHTHALMIC COMPOSITION BASED ON LIPID MICROPARTICLES CONTAINING AT LEAST ONE ACTIVE INGREDIENT AND PROCESS FOR PREPARING THE SAME.
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
DE69212850T2 (en) * 1991-01-15 1997-03-06 Alcon Lab Inc Use of carrageenan in topical ophthalmic compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9427578A1 *

Also Published As

Publication number Publication date
AU6940594A (en) 1994-12-20
SE9301877D0 (en) 1993-06-02
CA2164113A1 (en) 1994-12-08
WO1994027578A1 (en) 1994-12-08
JPH08510731A (en) 1996-11-12

Similar Documents

Publication Publication Date Title
KR940000229B1 (en) Process for preparing pharmaceutical composition of the type which undergoes liquid-gel phase transition
EP0844868B1 (en) Compositions including O-carboxymethyl chitosan and use in ophthalmics
US5106615A (en) Eyedrops having non-newtonian rheological properties
US9216167B2 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
IE69016B1 (en) Nonaqueous fluorinated drug delivery vehicle suspensions
US20100267664A1 (en) Ophthalmic compositions containing polysaccharide-borate gelling system
JP2003506478A (en) Tear substitute
EP0706372A1 (en) In situ gel for therapeutic use
FR2660193A1 (en) OPTHALMIC PRODUCT COMPRISING NANOCAPSULES, PROCESS FOR PREPARING THE SAME, AND USE OF NANOCAPSULES
EP1189595A1 (en) Ophthalmic compositions in form of aqueous gels
US5200180A (en) Pharmaceutical composition for the treatment of the human eye
AU760641B2 (en) Ophthalmic compositions and process of using
JP5041761B2 (en) Ocular mucosa application
BG64740B1 (en) Use of glycogen polysaccharide as active component for the production of ophthalmic solution
JPS63502270A (en) Ophthalmic pharmaceutical composition having mydriatic effect
JP2003267892A (en) Thermally gelatinizing artificial tear fluid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN AKTIEBOLAG

17Q First examination report despatched

Effective date: 19990212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990623